Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) announced a significant manufacturing milestone for its ONC010 program, successfully completing a 300-gram scale-up batch of the active pharmaceutical ingredient A83B4C63. The batch, produced under Dalton Pharma Services’ Process Optimization and Intermediate Scale-Up Program, achieved approximately 99.3% purity with no detectable residual solvents, according to the company’s quality control and Certificate of Analysis review.
This achievement marks a critical step forward for Onco-Innovations’ PNKP inhibitor program, demonstrating reproducibility and scalability of the manufacturing process. The company expects this scale-up to support future analytical qualification, formulation development, engineering batch production, and Good Manufacturing Practice (GMP) manufacturing activities ahead of planned First-in-Human studies. For the full press release, visit this link.
The news is important because it moves Onco-Innovations closer to clinical trials for ONC010, a drug candidate targeting solid tumors through patented technology. The company holds an exclusive worldwide license to this technology, which focuses on inhibiting PNKP, a DNA repair enzyme often overexpressed in cancer cells. Successfully scaling up the API ensures that sufficient high-purity material is available for the rigorous testing and production required before human trials can begin.
In addition to the manufacturing update, Onco-Innovations announced the appointment of Dave Antony as chief financial officer and corporate secretary, effective immediately. Antony succeeds Nico Mah. This leadership change comes at a pivotal time as the company advances its pipeline toward clinical development.
The implications for the biotechnology industry are noteworthy. Onco-Innovations’ progress with ONC010 could pave the way for new treatment options in oncology, particularly for solid tumors that are difficult to treat. The successful scale-up also validates the company’s manufacturing partnerships and technical capabilities, which are essential for attracting further investment and regulatory approvals.
For investors, the milestone provides tangible evidence of Onco-Innovations’ execution against its development roadmap. The company’s newsroom offers the latest updates at this link. As Onco-Innovations moves toward First-in-Human studies, the successful API scale-up reduces one of the key risks in drug development—manufacturing reliability.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions.
